McKesson HBOC makes drastic changes

Article

McKesson HBOC makes drastic changesThe board of directors at pharmaceutical supply and HIS firm McKesson HBOC has had enough with accounting improprieties at its Information Technology Business (formerly HBOC). Several key executives have

McKesson HBOC makes drastic changes

The board of directors at pharmaceutical supply and HIS firm McKesson HBOC has had enough with accounting improprieties at its Information Technology Business (formerly HBOC). Several key executives have resigned or been fired in the aftermath of the scandal.

The San Francisco-based company began by announcing the resignations of president and CEO Mark Pulido, and executive vice president and CFO Richard Hawkins, and the dismissal of Charles McCall.

In uncharacteristically strong language, the company also announced that four of its ITB unit executives had been dismissed immediately for cause: Albert Bergonzi, formerly president and CEO, David Held, CFO and controller, Jay Lupine, senior vice president and general counsel, and Michael Smeraski, senior vice president and head of enterprise sales.

In its first move toward rebuilding the ITB management team, the company named Graham King president of the unit, reporting to Hammergren.

Last month’s management changes arose out of the review of the ITB unit’s accounts, which found that the division had overstated its revenues. McKesson HBOC is continuing its internal audit, and intends to publish restated financial information as soon as possible. Although it does not expect to be able to file its 10-K with the Securities and Exchange Commission by the June 30 deadline, it hopes to do so shortly thereafter.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.